Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 67 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
DFP-11207の胆道がんに対する医師主導治験の症例登録開始に関するお知らせ
Regulatory Filings Classification · 75% confidence The document is a corporate press release in Japanese announcing the start of subject enrollment in a physician-led clinical trial for DFP-11207 in biliary tract cancer. It contains no financial statements, management changes, or shareholder vote results. It is an operational/regulatory announcement. There is no specific category for clinical trial notices, so by the fallback rule this is a general Regulatory Filing (RNS).
2026-06-04 Japanese
第11回新株予約権（行使価額修正条項付新株予約権）の 月間行使状況に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is a Japanese disclosure by Delta-Fly Pharma on the monthly exercise status of its 11th series stock acquisition rights (warrants). It details the number of warrants exercised, shares issued, exercise prices, and compliance with exercise restrictions. This is an announcement of a capital change due to issuance of shares upon warrant exercise. Therefore it fits the ‘Share Issue/Capital Change’ category (SHA).
2026-06-01 Japanese
Completion of Patient Enrollment for the Phase 2 Portion of DFP-17729 Phase 2/3 Randomized Study for Pancreatic Cancer in Japan
Regulatory Filings
2026-05-28 English
DFP-17729の臨床第2/3相比較試験の第２相部分の症例登録完了に関するお知らせ
Regulatory Filings Classification · 56% confidence The document is a corporate press release announcing the completion of subject enrollment in a Phase 2/3 clinical trial for DFP-17729. It contains no financial data, no meeting materials, no governance or voting information, and no regulatory form filings beyond a general corporate announcement. It is not itself a financial report but rather a miscellaneous regulatory/press announcement. Therefore, under our taxonomy it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-28 Japanese
DFP-10917の商標の国際登録とNDA承認取得の見通しに関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate announcement (“お知らせ”) regarding the international trademark registration of DFP-10917 trademarks and the outlook for NDA approval discussions with the FDA. It provides operational and regulatory updates rather than financial statements, meeting materials, or insider transactions. It does not fit into any specific category like earnings releases, capital changes, or M&A, so it falls under the generic Regulatory Filings category.
2026-05-11 Japanese
第11回新株予約権（行使価額修正条項付新株予約権）の 月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.